Clinical trials: Coronary; Ischemic
Coronary Artery Disease
PIvotal Trial of the KARDION Cory P4 MechANical Circulatory SupporT SystEm
This purpose of this trial is to demonstrate 30 day safety and effectiveness outcomes of the KARDION CORY P4 System in subjects who require hemodynamic support during a high-risk PCI procedure.
- Trial name
- NCT06445608
- Testing
- Percutaneous Mechanical Circulatory Support
- Where
- 18 sites in United States
- Volunteers
- 310 people
- Sponsor
- Kardion Inc
Coronary Artery Disease, Cardiovascular Diseases
Functional Diagnostic Accuracy of Quantitative Flow Ratio in Tandem Lesions and Virtual Stenting
Quantitative Flow Ratio (QFR) is a novel method for evaluating the functional significance of coronary stenosis. Virtual stent implantation technique combined with QFR was recently developed to predict the functional significance…
- Conditions
- Coronary Artery Disease, Cardiovascular Diseases, Myocardial Ischemia, Arterial Occlusive Diseases
- Trial name
- FORTRESS (NCT03405506)
- Testing
- Quantitative Flow Ratio (QFR)
- Where
- China
- Volunteers
- 308 people
- Sponsor
- Pulse Medical Imaging Technology (Shanghai) Co., Ltd
Acute Coronary Syndromes
ALIGN-ACS Pilot Study
The goal of this observational study is to evaluate the diagnostic performance of the HeartBeam ECG System for detection of acute coronary syndrome.
- Trial name
- ALIGN-ACS (NCT07715474)
- Testing
- ECG
- Where
- Serbia
- Volunteers
- 120 people
- Sponsor
- HeartBeam, Inc.
Coronary Artery Disease
A Single Center Study to Establish the Imaging Protocol of 99mTc-EC-DG in Evaluating the Presence and Severity of Coronary Artery Disease (CAD)
This study will assess the safety and tolerability of the investigational radiolabeled imaging agent technetium-99m-labeled ethylenedicysteine-deoxyglucose (99mTc-EC-DG).
- Trial name
- NCT01778218
- Testing
- Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Cell>Point LLC
Coronary Disease, Coronary Artery Disease
SPIRIT II: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System
Prospective, randomized, active-control, single blind, parallel two-arm multi-center clinical trial comparing XIENCE V® Everolimus Eluting Coronary Stent System to the approved commercially available active control TAXUS™…
- Conditions
- Coronary Disease, Coronary Artery Disease, Coronary Restenosis
- Trial name
- SPIRIT II (NCT00180310)
- Testing
- XIENCE V® Everolimus Eluting Coronary Stent, TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent
- Where
- 32 sites in Austria, Belgium and 11 more
- Volunteers
- 300 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW-III All-comers Orsiro Safety and Performance Registry
This registry is a clinical post-market evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES).
- Trial name
- BIOFLOW-III (NCT01553526)
- Where
- 43 sites in Austria, Chile and 11 more
- Volunteers
- 1,356 people
- Sponsor
- Biotronik AG
Coronary Artery Disease
Treatment of Coronary Artery Disease (CAD) With Bare Metal Stent (BMS) Followed by Paclitaxel-Coated Balloon Catheter Versus Paclitaxel-Eluting Stent
The purpose of this study is to compare the one-time application of Paclitaxel from SeQuent Please (Paclitaxel-coated Balloon Catheter) after using the Coroflex Blue (Cobalt Chromium Stent) with the slow releasing of small dose…
- Trial name
- NCT01166711
- Testing
- Coroflex Blue (BMS) followed by SeQuent Please (DEB), Coroflex Please (DES)
- Where
- Poland
- Volunteers
- 202 people
- Sponsor
- Aesculap AG
Myocardial Infarction
Full Dose Tenecteplase (TNK-tPA) Together With Heparin Sodium, Full Dose Tenecteplase With Enoxaparin, Half Dose Tenecteplase Together With Abciximab and Heparin Sodium in Patients With Acute Myocardial Infarction (AMI)
The objective of ASSENT 3 was to evaluate the safety and efficacy of full dose tenecteplase with heparin sodium (group A), full dose tenecteplase combined with enoxaparin (group B) and half dose tenecteplase combined with…
- Trial name
- ASSENT 3 (NCT02181985)
- Testing
- Full dose TNK-tPA, Half dose TNK-tPA, Heparin
- Volunteers
- 5,989 people
- Sponsor
- Boehringer Ingelheim
Coronary Arteriosclerosis, Acute Coronary Syndrome
GRAVITAS: Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety
The objective of the GRAVITAS trial is to determine whether tailored anti-platelet therapy using the Accumetrics VerifyNow P2Y12 assay reduces major adverse cardiovascular events after drug-eluting stent implantation.
- Trial name
- GRAVITAS (NCT00645918)
- Testing
- clopidogrel
- Where
- 82 sites in United States, Canada
- Volunteers
- 2,800 people
- Sponsor
- Accumetrics, Inc.
ST Elevation Myocardial Infarction
Evaluate the Efficacy and Safety of Allogeneic Umbilical Cord Mesenchymal Stem Cells as an Add-On Treatment for Acute ST-elevation Myocardial Infarction (STEMI) Patients
This phase IIa study is to identify the efficacy and safety of IC(intracoronary) and IV(Intravenous) administrations of UMSC01 in patients with STEMI .
- Trial name
- NCT06147986
- Testing
- Allogeneic umbilical cord mesenchymal stem cells, Control group
- Where
- Taiwan
- Volunteers
- 41 people
- Sponsor
- Ever Supreme Bio Technology Co., Ltd.
Coronary Artery Disease, Multi Vessel Coronary Artery Disease
Safety Study of Acellular Tissue Engineered Vessel for Coronary Artery Bypass
To assess safety and feasibility of a coronary bypass created with Vascudyne Acellular Tissue Engineered Vessel (ATEV) with External Support Structure (ESS) in patients requiring multi vessel coronary artery bypass grafting…
- Trial name
- VCAB-2 (NCT07078370)
- Testing
- ATEV with ESS
- Where
- 4 sites in Poland
- Volunteers
- 20 people
- Sponsor
- Vascudyne, Inc.
Hypercholesterolemia, Atherosclerosis
Switching to Rosuvastatin Versus Adding Ezetimibe to Atorvastatin Versus Doubling the Dose of Atorvastatin in Patients With Hypercholesterolemia and Risk Factors (P03708)
This study assesses whether adding ezetimibe 10 mg/d to ongoing treatment with atorvastatin 10 mg/d is more effective than switching the subject to treatment with rosuvastatin 10 mg/d or doubling the dose of atorvastatin to 20…
- Conditions
- Hypercholesterolemia, Atherosclerosis, Coronary Artery Disease
- Trial name
- NCT00651378
- Testing
- Rosuvastatin, Ezetimibe + Atorvastatin, Double Atorvastatin
- Volunteers
- 87 people
- Sponsor
- Organon and Co
Cardiovascular Diseases, Vascular Disease
An Observational Registry Using Drug Eluting Stents (DES) in Patients in a Real-World Setting (DEScover Registry).
The DEScover Registry is designed to observe the results of using Drug Eluting Stents (DES) in patients in a real-world setting.
- Conditions
- Cardiovascular Diseases, Vascular Disease, Arterial Occlusive Disease, Arteriosclerosis
- Trial name
- DESCOVER (NCT00489320)
- Testing
- Cypher Stent
- Where
- United States
- Volunteers
- 7,759 people
- Sponsor
- Cordis US Corp.
Cardiovascular Disease, Cerebrovascular Accident
A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels
The primary objective of this study is to determine the degree of additional reduction in cardiovascular risk that was accrued to patients by lowering their LDL-C beyond the currently accepted minimum target level for patients…
- Conditions
- Cardiovascular Disease, Cerebrovascular Accident, Coronary Heart Disease
- Trial name
- TNT (NCT00327691)
- Testing
- Atorvastatin
- Where
- 314 sites in United States, Australia and 12 more
- Volunteers
- 8,600 people
- Sponsor
- Pfizer
Acute Coronary Syndrome
Fondaparinux EU-RMP (Adherence)
Fondaparinux, a synthetic and specific factor Xa inhibitor, was granted an ACS indication by Health Canada in March 2007 and by the EMEA in September 2007.
- Trial name
- NCT01406301
- Testing
- fondaparinux
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Congestive Heart Failure, Coronary Artery Disease
Autologous Cultured Myoblasts (BioWhittaker) Transplanted Via Myocardial Injection
MyoCell™ implantation by epicardial injection during CABG surgery has the potential to add a new dimension to the management of post-infarct deterioration of cardiac function.
- Conditions
- Congestive Heart Failure, Coronary Artery Disease, Myocardial Infarction
- Trial name
- NCT00050765
- Testing
- MyoCell™ Autologous Myoblasts
- Where
- 5 sites in United States
- Volunteers
- 15 people
- Sponsor
- Bioheart, Inc.
Coronary Artery Disease
Latin America Real World Study With Inspiron Drug Eluting Stent - INSPIRON LATITUDE
Prospective, multicenter, single arm registry to monitor post-market clinical outcomes of patients treated with Inspiron Sirolimus-Eluting Stent with Biodegradable Polymer.
- Trial name
- LATITUDE (NCT03471234)
- Testing
- Angioplasty
- Where
- 2 sites in Brazil
- Volunteers
- 299 people
- Sponsor
- Scitech Produtos Medicos SA
Coronary Artery Disease
Photochemical Tissue Passivation Treatment of Saphenous Vein Grafts in CABG
Early feasibility study of the DurVena Photochemical Tissue Passivation (PTP) device for treatment of saphenous vein grafts in participants undergoing elective coronary artery bypass graft (CABG) surgery.
- Trial name
- NCT06150872
- Testing
- DurVena Photochemical Tissue Passivation
- Where
- Uzbekistan
- Volunteers
- 4 people
- Sponsor
- DurVena, Inc.
CAD - Coronary Artery Disease
Angiogram Based Fractional Flow Reserve FFRangio - A Validation Study
In the present study we aim at validating the computation of FFRangio values from the angiogram by comparing them to measured wire-based FFR values, in a larger scale and in a completely blinded manner.
- Trial name
- NCT03005028
- Where
- Israel
- Volunteers
- 184 people
- Sponsor
- CathWorks Ltd.
Coronary Artery Disease
AZD5718 Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of Oral AZD5718 in Patients With Coronary Artery Disease (CAD).
This is a randomized, single-blind, placebo-controlled, parallel-group, multicentre study in patients with CAD. The study will be conducted at approximately 10 centres in 3 countries.
- Trial name
- FLAVOUR (NCT03317002)
- Testing
- AZD5718
- Where
- 9 sites in Denmark, Finland and 1 more
- Volunteers
- 129 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.